Back to search results

Real-world Experience Using Nemolizumab for Atopic Dermatitis

This study is looking at how well nemolizumab (Nemluvio®) works in real-world settings for adolescents and adults (age 12 and older) with moderate-to-severe atopic dermatitis (eczema). Researchers want to see how effective nemolizumab is after 6 months, based on what doctors observe and what patients report about their symptoms, especially itching. You could be eligible if your doctor decides to start you on nemolizumab and you have moderate-to-severe eczema. The study aims to enroll about 1000 participants, but its current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will collect information from your routine medical care. It is not a clinical trial where you would be assigned a specific treatment.
What's involved
You would continue your routine medical visits as determined by your doctor. No extra visits, procedures, or lab tests are required beyond your usual care.
Compensation
Not stated in the trial record.
Follow-up
The primary effectiveness measures are taken at Month 6, and the study will follow participants for approximately 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06988605

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Recruiting
Not specifiedAges 12+Observational
Galderma R&D
~1,000 participants
Updated 2026-03-13 on ClinicalTrials.gov

At a glance

Recruiting sites
81 of 108 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Investigator Global Assessment (IGA) at Month 6
Measured over At Month 6
+1 more outcome measured

Conditions

Atopic Dermatitis

Explore related trials

Atopic Dermatitis

Where it's being run

108 sites across 37 states
Germany19
United Kingdom14
Florida10
California7
New York6
Texas6
Arizona4
Michigan4

Who to contact

Galderma Research and Development
[email protected]
817-961-5000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.

Exclusion

Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
Participants who received nemolizumab previously.
Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

What this trial measures

  • Investigator Global Assessment (IGA) at Month 6At Month 6

    The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of AD and the clinical response to a treatment.

  • Peak Pruritus Numerical Rating Scale (PP NRS) at Month 6At Month 6

    The PP NRS is a single question validated PRO assessment that participants will use to report the maximum intensity of their pruritus (itch). The PP NRS consists of the following question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Here, a lower score indicates a better outcome.